A novel percutaneous technique for accessing the normal pericardium: A single-center successful experience of 53 porcine procedures

Journal of Invasive Cardiology

Volumn 15, Issue 1, 2003, Pages 13-16

  Hou, Dongming ^a,c   March, Keith L ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Intrapericardial delivery; PerDUCER ; Pericardium

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CORONARY ARTERY DISEASE; DEVICE; DIAGNOSTIC TEST; DRUG DELIVERY SYSTEM; FEMALE; HEART DISEASE; HEMODYNAMICS; HISTOLOGY; NONHUMAN; PERICARDIAL EFFUSION; PERICARDIUM; SAFETY; SWINE; TECHNIQUE;

ANIMALS; EQUIPMENT DESIGN; FEMALE; HEART CATHETERIZATION; PERICARDIECTOMY; PERICARDIUM; SWINE;

EID: 0037251289     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Spodick DH. Physiology of the normal pericardium: Functions of the pericardium. In: Spodick DH. The Pericardium: A Comprehensive Textbook. New York: Marcel Dekker, 1997: pp. 15-26.
2. Hou D, March KL. Intrapericardial approach for therapeutic angiogenesis. In: Kornowski R, Leon MB (eds). Handbook of Myocardial Revascularization and Angiogenesis. London, Martin-Dunitz, 1999: pp. 190-200.
3. Hou D, Rogers PI, Toleikis PM, et al. Intrapericardial paclitaxel delivery inhibits neointimal proliferation and promotes arterial enlargement after porcine coronary overstretch. Circulation 2000;102:1575-1581.
4. Baek SH, Hrabie JA, Keefer LK, et al. Augmentation of intrapericardial nitric oxide level by a prolonged-release nitric oxide donor reduces luminal narrowing after porcine coronary angioplasty. Circulation 2002;105:2779-2784.
5. Fei L, Baron AD, Henry DP, Zipes DP. Intrapericardial delivery of L-arginine reduces the increased severity of ventricular arrhythmias during sympathetic stimulation in dogs with acute coronary occlusion: Nitric oxide modulates sympathetic effects on ventricular electrophysiological properties. Circulation 1997;96:4044-4049.
6. Comedicus, Incorporated: PerDUCER® model 830 pericardial access device. In: Leon MB, Mintz GS (eds). Interventional Vascular Product Guide. London, Martin-Dunitz, 1999: pp. 396-402.
7. Uchida Y, Yanagisawa-Miwa A, Fumitake N, et al. Angiogenic therapy of acute myocardial infarction by intrapericardial injection of basic fibroblast growth factor and heparin sulfate. Am Heart J 1995;130:1182-1188.
8. Waxman S, Lovett EG, Verrier RL. New technique for rapid, safe transvenous access into the pericardial space: A novel approach for local cardiac drug delivery. J Am Coll Cardiol 1998;31(Suppl A):426A.
9. Verrier RL, Waxman S, Lovett EG, Moreno R. Transatrial access to the normal pericardial space: A novel approach for diagnostic sampling, pericardiocentesis, and therapeutic interventions. Circulation 1998;98:2331-2333.
10. Stoll HP, Carlson K, Keefer LK, et al. Pharmacokinetics and consistency of pericardial delivery directed to coronary arteries: Direct comparison with endoluminal delivery. Clin Cardiol 1998;21(Suppl III):III-10-III-16.
11. Seferovic PM, Ristic AD, Maksimovic R, et al. Initial clinical experience with the PerDUCER® device: Promising new tool in the diagnosis and treatment of pericardial disease. Clin Cardiol 1999;22(Suppl I):I-30-I-35.
12. Macris MP, Igo SR. Minimally invasive access of the normal pericardium: Initial clinical experience with a novel device. Clin Cardiol 1999;22(Suppl I):I-36-I-39.